MicroRNAs in atherosclerosis  by Chen, Ku-Chung & Juo, Suh-Hang Hank
Kaohsiung Journal of Medical Sciences (2012) 28, 631e640Available online at www.sciencedirect.com
journal homepage: http: / /www.kjms-onl ine.comREVIEW ARTICLE
MicroRNAs in atherosclerosisKu-Chung Chen a,b, Suh-Hang Hank Juo a,b,*aDepartment of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
bDepartment of Medical Genetics, Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Received 3 January 2012; accepted 20 February 2012
Available online 5 August 2012KEYWORDS
Atherosclerosis;
Cardiovascular
disease;
MicroRNA* Corresponding author. Kaohsiung M
1st Road, Kaohsiung 807, Taiwan.
E-mail address: hjuo@kmu.edu.tw
1607-551X/$36 Copyright ª 2012, Else
doi:10.1016/j.kjms.2012.04.001Abstract MicroRNAs are endogenously expressed small noncoding RNAs that regulate gene
expression at the post-transcriptional level. MicroRNAs have emerged as key regulators of
several physiological and pathophysiological processes in the cardiovascular system. Aberrant
expression of microRNAs has been implicated in the pathophysiological processes underlying
the development of atherosclerosis and cardiovascular disease, including change in endothe-
lial function, vascular smooth muscle cell proliferation and migration, macrophage function,
and foam cell formation. In this review, we summarize the recent data showing the roles of
microRNAs in cell studies, studies on atherosclerotic mice, and human studies.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Introduction
Atherosclerosis is a major risk factor for cardiovascular
disease [1]. Endothelial cells dysfunction often initiates
a series of changes that leads to the development of
atherosclerosis. Atherosclerotic plaques are composed of
accumulated lipid particles in foam cells, proliferated
vascular smooth muscle cells (VSMCs), and extracellular
matrix. These plaques are landmarks of advanced athero-
sclerotic lesions in the artery. Therefore, endothelial cells,
VSMCs, and macrophage-derived foam cells are critical
players in the development of plaques [2e5]. Several genes
and cytokines have been identified as risk factors foredical University, 100 TzYou
(S.H. Juo).
vier Taiwan LLC. All rights reservatherosclerosis [6,7], and recent studies have suggested
that microRNAs (miRNAs) may play a role in regulating the
atherosclerotic process [8,9].
miRNAs are a novel class of endogenous noncoding,
single-stranded RNAs with a length of approximately 22
nucleotides. A miRNA controls gene expression by binding
to its target genes’ messenger RNAs (mRNAs) for degrada-
tion and/or translational repression [10]. In animals
(including humans), this gene-silencing effect is mediated
by a complementary base pairing between the 30 untrans-
lated region of the mRNA and a particular region of
a miRNA. This particular region of miRNA is called the “seed
region” and is located at positions 2e8 of a miRNA. miRNAs
can be expressed in a tissue- and cell-type specific manner
and affect multiple cell functions such as proliferation,
apoptosis, migration, differentiation, and also develop-
ment [11]. Accumulating evidence has demonstrated the
role and function of miRNAs in maintaining normal physio-
logical conditions and disease development.ed.
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the role of miRNAs in the cardiovascular system has been
gradually revealed. Hence, this is a pertinent time to
review and summarize the recent findings on miRNAs in the
context of atherosclerosis. This review article describes the
role of miRNAs in three areasdendothelial cells, VSMCs,
and macrophages (Table 1).Table 1 Function of microRNAs in atherosclerosis.
MicroRNA Functions Targets
Endothelial cells
miR-21 Proatherosclerotic PTEN
Antiapoptotic PPARa
miR-126 Antiatherosclerotic VCAM-1
Anti-inflammatory
Antiapoptotic
miR-217 Proatherosclerotic SirT1
Antiangiogenic
miR-221/222 Antiatherosclerotic c-Kit
Antiangiogenic STAT5A
miR-10a Antiatherosclerotic MAP3K7
Anti-inflammatory TRC
miR-365 Proatherosclerotic Bcl-2
Apoptotic
miR-663 Proatherosclerotic IL8
Inflammatory ATF3
KLF4
miR-125a-5p/125b-5p Antiatherosclerotic ET-1
miR-34a Proatherosclerotic SirT1
Apoptotic
miR-146a Antiatherosclerotic NOX4
Anti-inflammatory CD40L
miR-200 Proatherosclerotic ZEB1
Apoptotic Ets-1
miR-210 Proatherosclerotic Ephrin-A3
Apoptotic
Vascular smooth muscle cells
miR-145/-143 Antiatherosclerotic KLF4/KLF5
Myocardin
Nkx2-5
Elk-1
miR-26a Proatherosclerotic SMAD
Antiapoptotic
miR-29 Proatherosclerotic DNMT3A /3B
Collagens
Fibrillins
Elastin
miR-1/-133 Antiatherosclerotic CDK-9
KLF4
Sp-1
miR-24 Proatherosclerotic Trb3
miR-208 Proatherosclerotic p21
Let-7 Antiatherosclerotic KRAS
LOX-1
Macrophages
miR-125a-5p Proatherosclerotic ORP9
miR-155 Antiatherosclerotic MyD88
miR-150 Proatherosclerotic c-Myb
VMSC Z vascular smooth muscle cell. For all other abbreviations, seemiRNAs in endothelial cells
The endothelium has a pivotal role in maintaining vascular
homeostasis and in providing a physical barrier between
the blood components and the subendothelial space
[12e14]. Endothelial dysfunction has recently been
demonstrated to be an early step in the development ofPhenotype Reference
Neointimal lesion formation [17e21]
Endothelial dysfunction
Inhibits angiogenesis and inflammation [23,24]
Cell senescence [26]
Inhibit angiogenesis [28,32]
Lower levels in athero-susceptible regions [38]
Endothelial cell apoptosis [39]
Inflammatory response [40]
Inhibit endothelial dysfunction [43]
Cell senescence [19,45]
Inhibit cell senescence [48,49]
Anti-inflammatory
Cell senescence [52e54]
Apoptosis
Angiogenesis [56]
Inhibit neointimal lesion formation [68e73]
Regulate VSMC phenotype switch
VSMC proliferation [74]
VSMC migration [77e79]
Cell senescence
Inhibit VSMC proliferation [83e85]
VSMC phenotype switch [86]
VSMC proliferation [87]
Inhibit VSMC proliferation [89e91]
Foam cell formation [93]
Inhibit inflammatory response [94,95]
Cell migration [96]
text.
MicroRNAs in atherosclerosis 633atherosclerosis, and it has also been shown to contribute
to the formation, progression, and complications of
atherosclerotic plaques [14]. Importantly, endothelial
dysfunction represents a common link among all known
cardiovascular risk factors, including dyslipidemia,
smoking, diabetes, hypertension, obesity, and mental
stress [15]. Several features can characterize endothelial
dysfunction, including a reduced bioavailability of nitric
oxide, increased expression of adhesion molecules,
increased levels of proinflammatory and prothrombotic
factors, oxidative stress, and abnormal modulation of
vascular tone. Several miRNAs have been reported to be
related to endothelial dysfunction, and these are
summarized below.
miR-21
miR-21 is one of the most dynamically regulated miRNAs in
various pathological processes, ranging from cancer to
cardiovascular disease [16]. Aberrant expression of miR-21
is found in vascular neointimal lesion formation and acute
myocardial infarction [17,18]. miR-21 is significantly upre-
gulated in atherosclerotic plaques compared with non-
atherosclerotic arteries [19]. Using the shear stress
treatment on endothelial cells, the expression levels of
miR-21 are greatly increased [20]. In addition, the same
study [20] reported that miR-21 causes an antiapoptotic
effect, increased endothelial nitric oxide synthase phos-
phorylation, and nitric oxide production in endothelial cells
by directly targeting to PTEN, a known tumor suppressor
gene. However, another study using shear stress in endo-
thelial cells reported that overexpressed miR-21 may
inhibit the expression of peroxisome proliferator-activated
receptor-alpha (PPARa), leading to enhanced expressions
of vascular cell adhesion molecule-1 (VCAM-1) and mono-
cyte chemotactic protein-1 [21]. The studies mentioned
indicate a critical role of miR-21 in the development of
atherosclerosis, but whether an increase in miR-21 in
endothelial cells is beneficial or deleterious remains to be
clarified.
miR-126
miR-126 is expressed only in endothelial cells, and thus it is
recognized as an endothelium-specific microRNA for regu-
lating angiogenesis and vascular inflammation. A low level
of circulating miR-126 is associated with peripheral vascular
complications in patients with type 2 diabetes and
myocardial infarction [22,23]. miR-126 possesses an ability
to regulate monocyte adhesion by directly targeting VCAM-
1, and thus it controls vascular inflammation [24]. A
potential E26 transformation-specific sequence (Ets)
binding site is located between e71 and e100 bp upstream
of the miR-126 gene [25]. Either transcription factor Ets-1
or Ets-2 may activate the expression of miR-126, resulting
in depression of VCAM-1. Additionally, administration of
miR-126 in mouse models of atherosclerosis may reduce
macrophage and apoptotic cell content, thereby limiting
lesions size and conferring a milder inflammatory reaction
[23]. Accordingly, miR-126 may exert an antiatherosclerotic
effect.miR-217
Aging is a major risk factor for the development of
atherosclerosis and coronary artery disease. Since endo-
thelial cell senescence contributes to age-related impair-
ment of angiogenesis, miRNAs involved in senescence
processes may be also related to atherosclerosis formation.
Menghini et al demonstrated that miR-217 is largely
expressed in aged but not young endothelial cells [26].
They also identified that silent information regulator-1
(SirT1), a major regulator in metabolic disorders, is
a direct target gene of miR-217. Overexpression of miR-217
can induce endothelial cell senescence formation.
Conversely, inhibition of miR-217 in elderly endothelial
cells ultimately reduces senescence and increases angio-
genic activity. Although miR-217 functions as a potential
tumor suppressor by targeting KRAS [27], miR-217 exerts
negative effects on the vascular endothelium by enhancing
endothelial senescence, which is related to pathogenesis of
cardiovascular diseases.
miR-221/222
miR-221 and miR-222 (miR-221/222) belong to the same
family, and their genes are located in the same cluster gene
on Xp11.3 chromosome. miR-221/222 were identified as
antiangiogenic miRNAs by inhibiting c-Kit-mediated migra-
tion in endothelial cells [28]. Furthermore, levels of miR-
221/222 are significantly higher in endothelial progenitor
cells from individuals with coronary artery disease than in
those without [29,30]. Notably, circulating endothelial
progenitor cells play an important role in the maintenance
of endothelial integrity and vascular repair [31]. Several
proteins have been identified as target genes of miR-221/
222, including signal transducer and activator of tran-
scription 5A (STAT5A), a transcription factor involved in the
regulation of cell proliferation and migration. STAT5A has
been shown to increase along with reduced miR-222 in
endothelial cells from advanced neovascularized athero-
sclerotic lesions [32]. Overexpression of miR-221/222
effectively decreases the adhesion of Jurkat T cells to
Angiotensin II-stimulated endothelial cells by inhibiting
expression of Ets-1, a key endothelial transcription factor
for inflammation and tube formation [33]. Thus, miR-221
and miR-222 have effects on regulation of angiogenesis
during the development of atherosclerosis.
miR-10a
Disturbed flow in arteries may lead to atherosclerosis
formation. Conversely, the regions of undisturbed laminar
flow are more resistant to atherosclerosis [34]. The endo-
thelium in athero-susceptible regions displays different
characteristics, including those related to sensitization of
inflammatory regulators, redox/lipid balance, and endo-
plasmic reticulum stress, from epithelium located at
athero-resistant sites [35e37]. The expression of endothe-
lial miR-10a is lower in the athero-susceptible regions of
the inner aortic arch and aortorenal branches than else-
where [38]. Knockdown of miR-10a in cultured human
aortic endothelial cells can induce inflammatory processes
634 K.-C. Chen, S.H. Juomediated by inhibitor of kappa B/nuclear factor kappa B
(IkB/NF-kB). The genes encoding mitogen-activated protein
kinase kinase kinase 7 (MAP3K7; TAK1) and beta-transducin
repeat-containing (bTRC), which are two key regulators of
IkBa degradation, have been identified as direct target
genes of miR-10a. Both MAP3K7 and bTRC are upregulated
when miR-10a is knocked down, which leads to enhanced
NFkB activation.
miR-365
Endothelial cells apoptosis can contribute to the develop-
ment of atherosclerosis. The presence of oxidized low-
density lipoprotein (oxLDL) is an important risk factor for
atherosclerosis and contributes greatly to the apoptosis of
endothelial cells. miR-365 has been identified to be upre-
gulated in endothelial cells upon oxLDL treatment [39].
miR-365 directly targets the antiapoptotic protein B-cell
CLL/lymphoma 2 (Bcl-2) and promotes cell death. Knock-
down of miR-365 represses oxLDL-mediated apoptosis of
endothelial cells, suggesting that miR-365 may be a poten-
tial novel therapeutic target for atherosclerosis.
miR-663
Recently, upregulation of miR-663 by oscillatory shear
stress has been identified as playing a role in inflammatory
response of endothelial cells [40]. miR-663 mediates oscil-
latory shear stress-induced monocyte adhesion to the
endothelial cells via tumor necrosis factor alpha (TNF-a)
activation, but it does not affect the oscillatory shear
stress-mediated apoptosis of endothelial cells. Several miR-
663 target genes such as IL8, ATF3, and KLF4 regulate
important physiological processes including cell prolifera-
tion and inflammatory response that are involved in
atherosclerosis. Accordingly, miR-663 is likely to play a role
in the proatherosclerotic process.
miR-125a-5p/125b-5p
Endothelin-1 (ET-1) is a 21-amino-acid peptide that acts on
seven transmembrane G protein-coupled receptors to elicit
a plethora of responses [41]. Elevated levels of circulating
ET-1 have been shown to be associated with endothelial
dysfunction and dysregulation of vascular function [42]. ET-
1 is a direct target gene of miR-125a-5p and miR-125b-5p,
and both miRNAs are highly expressed in vascular endo-
thelial cells [43]. miR-125a/125b-5p can suppress oxLDL-
induced ET-1 expression, and thus both miRNAs play
a protective role against development of atherosclerosis.
miR-34a
miR-34a is highly expressed in endothelial cells [44], and
elevated miR-34a expression can be observed in senescent
endothelial cells, heart, and spleen of aged mice. The
overexpression of miR-34a induces endothelial cell senes-
cence and also suppresses cell proliferation by inhibiting
the cell cycle via directly inhibiting SirT1 protein expression
[45]. miR-34a expression is significantly upregulated in
atherosclerotic arteries versus nonatherosclerotic leftinternal thoracic arteries [46]. The current evidence
suggests that miR-34a can promote the formation of
atherosclerosis.
miR-146a
miR-146a also has a modulatory effect in endothelial cell
senescence [47]. miR-146a is downregulated in aged
endothelial cells. It can directly target NADPH oxidase-4
(NOX4), which implicates it in cell senescence and aging.
The expression of miR-146a is decreased under oxLDL
stimulation [48], while miR-146a significantly reduces
intracellular LDL cholesterol content and secretion of
interleukin-6 (IL-6) and IL-8, chemokine (C-C motif) ligand-
2, and matrix metallopeptidase-9 (MMP-9) in macrophages
[48]. In addition, miR-146a can inhibit the activation of
Toll-like receptor 4 (TLR4)-dependent intracellular
signaling pathways, which are involved in cytoskeleton
rearrangement, lipid uptake, and inflammatory cytokine
secretion [48]. miR-146a also regulates the maturation
process and proinflammatory cytokine secretion by target-
ing CD40L in ox-LDL-stimulated dendritic cells [49].
Furthermore, overexpression of miR-146a in peripheral
blood mononuclear cells significantly upregulates the
function of T helper type 1 cells [50]. The upregulation of
these cells has been suggested to have an essential function
in the development of atherosclerosis. Overexpression of
miR-146a may therefore prevent atherosclerosis.
miR-200
Recently, the miR-200 family has been shown to inhibit cell
migration and modulate epithelialemesenchymal transition
in cancer cells [51]. Members of the family also play
a causal role in a variety of cardiovascular diseases. miR-
200c is upregulated in oxidative stress-mediated endothe-
lial cells [52]. Overexpression of miR-200c induces growth
arrest, apoptosis, and senescence via directly targeting
zinc finger E-box binding homeobox-1 (ZEB1), a prosurvival
protein. Hypoxia induces downregulation of miR-200b and
promotes angiogenesis [53]. Delivery of miR-200b mimic to
endothelial cells can suppress the angiogenic response
through downregulation of v-ets erythroblastosis virus E26
oncogene homolog 1 (Ets-1), a crucial angiogenesis-related
transcription factor. miR-200b can also reduce protein
levels of vascular endothelial growth factor (VEGF), fms-
related tyrosine kinase-1 (Flt-1), and kinase insert domain
receptor (KDR), resulting in an inhibition of endothelial
angiogenesis [54]. These results suggest that the miR-200
family may be a therapeutic target for the prevention of
atherosclerosis.
miR-210
Hypoxia can induce the development of atherosclerosis.
The hypoxia-inducible factor pathway is essential for cell
survival under conditions of low oxygen and enhances
endothelial cell angiogenesis [55]. miR-210 has been shown
to be a prominent miRNA that is upregulated by hypoxia.
Overexpression of miR-210 in normoxic endothelial cells
stimulates the formation of capillary-like structures and
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regulation [56]. Anti-miR-210 inhibits cell growth and
induces apoptosis in both normoxic and hypoxic conditions.
In our unpublished data, we also found that dysregulation
of miR-210 is involved in the formation of atherosclerosis.
Thus, miR-210 may be another therapeutic target in
atherosclerosis therapy.
In addition to the miRNAs mentioned above, several
miRNAs are also reported to be involved in endothelial
dysfunctions related to angiogenesis, including miR-424,
miR-373, miR-16, and miR-296 [55,57,58].
miRNAs regulate vascular smooth muscle cells
VSMC plasticity plays an important role in vascular pathol-
ogies during the development of atherosclerosis. VSMCs
maintain an organized, differentiated, and contractile
phenotype under physiological conditions. Upon inappro-
priate stimulation, these contractile cells may be switched
to a proliferative and migratory (synthetic migratory)
phenotype [59]. In atherosclerosis, the switch of VSMC
phenotype contributes to neointima and plaque formation.
A wide variety of growth factors, such as platelet-
derived growth factor (PDGF) and insulin-like growth
factor-I, have been identified to participate in the regula-
tion of VSMC proliferation and migration [60]. In particular,
recent findings have also demonstrated that miRNAs play
a critical role in the switch of VSMC phenotype. Several
endothelial miRNAs also show their effects on VSMC.
Increased miR-21 regulates VSMC function via targeting
tropomyosin-1, programmed cell death protein-4 (PDCD4),
sprouty-2 (SPRY2), and PPARa in arteriosclerosis [61e63].
miR-146a and Kruppel-life factor-4 (KLF4) form a feedback
loop to regulate each other’s expression and VSMC prolif-
eration [64]. miR-10a is identified as a novel regulator in
VSMC differentiation from embryonic stem cells via tar-
geting histone deacetylase-4 (HDAC4) [65]. The expression
of miR-221 and miR-222 is upregulated and localized in the
VSMCs of injured vascular walls, resulting in VSMC prolif-
eration and neointimal hyperplasia [66,67]. Below, we
introduce more miRNAs whose functions are specifically
identified in the regulation of VSMC phenotype.
miR-145/143
miR-143 and miR-145 are contained in a bicistronic primary
transcript from chromosome 5. The genes for miR-143/145
are also identified as a cluster gene. Zhang and coworkers
demonstrated that miR-145 was abundant in normal
arteries and VSMCs [68,69]. The expression of miR-145 is
significantly downregulated in dedifferentiated VSMCs and
in balloon-injured arteries. These authors also identified
that miR-145 was a novel VSMC phenotypic marker and
modulator that is able to control vascular neointimal lesion
formation. Several VSMC differentiation marker genes, such
as smooth muscle alpha-actin, calponin, and smooth
muscle-myosin heavy chain (SM-MHC), are upregulated by
miR-145 via targeting KLF5.
Cordes et al also reported that miR-145 and miR-143 are
direct transcriptional targets of serum response factor,
myocardin, and NK2 transcription factor related, locus 5(Nkx2-5), and that they are downregulated in injured or
atherosclerotic vessels containing proliferating, less
differentiated VSMCs [70]. Furthermore, miR-145 and miR-
143 cooperatively target a network of transcription
factors, including KLF4, myocardin, and ELK1, member of
ETS oncogene family (Elk-1), to promote differentiation
and repress proliferation of VSMCs. Transforming growth
factor beta (TGF-b) and bone morphogenetic protein-4
(BMP4) downregulate KLF4 expression through upregula-
tion of miR-143 and miR-145, which results in the inhibition
of VSMC growth and migration [71,72]. TGF-b activates
transcription of the miR-143/145 gene cluster through the
CArG box via myocardin expression, while BMP4 exerts
a similar effect via nuclear translocation of myocardin-
related transcription factor-A.
Moreover, loss of miR-143/145 results in the formation of
podosomes, which are actin-rich membrane protrusions
that are involved in VSMC migration [73]. PDGF can mediate
podosome formation in VSMCs through the regulation of
miR-143/145 expression via a pathway involving Src and
p53. All the evidence indicates that miR-143/145 play
important roles in controlling VSMC cell fate and plasticity
during atherosclerosis.
miR-26a
Recently, miR-26a has been identified as a novel regulator
of VSMC function [74]. Inhibition of miR-26a promotes VSMC
differentiation, enhances cell apoptosis, and increases
expression of the SMAD1 and SMAD4 genes. miR-26a is
significantly downregulated in murine abdominal aortic
aneurysm in which VSMCs show dedifferentiation and
apoptosis. However, reports of miR-26a in VSMC are very
limited, and more studies are needed to elucidate its role in
VSMC and atherosclerosis.
miR-29
The miR-29 family contains miR-29a, miR-29b, and miR-29c.
miR-29 reverts aberrant methylation in cancer formation by
targeting DNA methyltransferases (DNMT) 3A and 3B, two
key enzymes that are involved in DNA methylation [75].
miR-29 also inhibits the expression of several extracellular
matrix-related proteins, including multiple collagens,
fibrillins, and elastin [76]. In senescent and aged cells, the
expressions of the miR-29 family are upregulated [77,78].
Previously, we showed that oxLDL could enhance miR-29b
expression through the lectin-like oxidized low-density
lipoprotein receptor 1 (LOX-1)-mediated reactive oxygen
species (ROS) generation pathway [79]. We further showed
that miR-29b indirectly promotes MMP2/MMP9 gene hypo-
methylation via targeting DNMT3b, which results in gene
upregulation. The current data suggest that an increase in
miR-29 may lead to cardiovascular diseases.
miR-1/133
miR-1 and miR-133 are cluster genes, and they play
a crucial role in the biology and pathophysiology of skel-
etal/cardiac muscle [80]. They also regulate myocardial
differentiation of mouse embryonic stem cells via targeting
636 K.-C. Chen, S.H. Juoto cyclin-dependent kinase-9 [81]. Although the expressions
of miR-1/133 are decreased during skeletal muscle hyper-
trophy [82], overexpression of these two miRNAs inhibits
VSMC proliferation via the target genes KLF4 and Sp1,
respectively [83e85].
miR-24
Both BMP and TGF-b signaling pathways promote
a contractile phenotype in the VSMC, while the platelet-
derived growth factor beta polypeptide (PDGF-BB) signaling
pathway promotes a switch to the synthetic phenotype.
Chan et al demonstrated that PDGF-BB induces miR-24
upregulation via its target gene of Tribbles-like protein-3
(Trb3) [86]. Repression of Trb3 causes VSMC to become
a synthetic phenotype, and it is the synthetic phenotype
that underlies the generation of atherosclerotic lesions.
miR-208
Aberrant expression of miR-208 affects VSMC proliferation
[87]. Zhang et al demonstrated that insulin upregulated
miR-208 expression and increased VSMC proliferation. They
also showed that miR-208 downregulated its target gene,
p21, to promote insulin-induced VSMC proliferation.
Let-7
miRNA let-7 has nine family members in humans. The let-7
family play a pivotal role in cancer development, being
tumor-suppressive miRNAs [88]. However, most of their
functions in cardiovascular diseases have only recently
been identified. Kuehbacher et al have reported that let-7f
can promote angiogenesis by targeting the antiangiogenic
gene for thrombospondin-1 [89], and Yu et al have reported
that let-7d can directly target KRAS to inhibit VSMC prolif-
eration [90].
Our laboratory recently reported that oxLDL inhibited
let-7g expression via a LOX-1/ROS/ERK/AP-1 pathway [91]
and, inversely, let-7g could directly target LOX-1 to
comprise a negative feedback regulation that was involved
in VSMC proliferation and migration. Our unpublished data
also indicate that downregulation of let-7g may be involved
in the specific inflammatory pathway, leading to chronic
inflammation in the cardiovascular system.
miRNAs in macrophages
Macrophages are cells involved in the innate immune
system, aiding the clearance of apoptotic cells and the
removal of cellular debris generated by tissue remodeling
and cellular necrosis [92]. Macrophages can release
inflammatory substances that influence atherosclerosis.
Macrophages are derived from monocytes under the control
of specific cytokine signals. The lipid-laden macrophages
are named foam cells, and they contribute significantly to
the formation of atherosclerotic lesions. The process of
foam cell formation involves retention of LDL in the
vascular wall and its modification via oxidation, followed by
excessive uptake by macrophages that eventually become
foam cells. The mechanism(s) underlying macrophagedifferentiation into foam cells are complex and not yet fully
characterized. Recently, several studies have reported that
miRNAs play important roles in foam cell formation and
inflammation in atherosclerosis.
miR-125a-5p
miR-125a-5p plays a role in endothelial dysfunction as well
as in foam cell formation. By using miRNA microarray
analysis, Chen et al found that five miRNAsdmiR-125a-5p,
miR-9, miR-146a, miR-146b-5p, and miR-155dwere upre-
gulated in oxLDL-stimulated monocytes [93], whereas miR-
128 and miR-15a were downregulated. Furthermore, miR-
125a-5p was found to mediate lipid uptake and to
decrease the secretion of some inflammatory cytokines (IL-
2, IL-6, TNF-a, TGF-b) from monocyte-derived macrophages
via targeting oxysterol binding protein-like 9 (ORP9).
miR-155
miR-155 is an important regulator in the immune system
and has been shown to be involved in the acute inflam-
matory response [94]. The dose-dependent upregulation of
miR-155 was found in oxLDL-treated macrophages [95].
Silencing of endogenous miR-155 in macrophages signifi-
cantly enhances lipid uptake, upregulates the expression of
scavenger receptors, and promotes the release of several
cytokines including IL-6, IL-8, and TNF-a [95]. miR-155
can promote NFkB nuclear translocation and activate the
NFkB pathway. These findings demonstrate that miR-155
serves as a negative feedback regulator for inflammatory
responses and lipid uptake in macrophages.
miR-150
miR-150 can be selectively packaged into microvesicles and
actively secreted from cells of the human THP-1 monocyte
cell line [96]. These THP-1-derived microvesicles can enter
and deliver miR-150 into the endothelial cells. The elevated
exogenous miR-150 effectively reduces v-myb myelo-
blastosis viral oncogene homolog (c-Myb) expression and
enhances cell migration in endothelial cells. Furthermore,
microvesicles isolated from the plasma of patients with
atherosclerosis contained higher levels of miR-150 than did
those of controls. These results not only demonstrate the
role of miR-150 in atherosclerosis development, but also
suggest that secreted miRNAs can be delivered into recip-
ient cells to influence recipient cell function.
miR-147
Recently, the stimulation of TLR signaling by bacterial
lipopolysaccharides has been shown to promote the accu-
mulation of lipid in macrophages and consequently foam
cell formation [97]. Understanding the mechanisms of TLR
signaling pathways may provide more insight into foam cell
formation. Several miRNAs have been reported to regulate
TLR signaling pathways. miR-146a inhibits accumulation of
oxLDL-induced lipid and the inflammatory response via
targeting TLR4 [48], and miR-147 can be induced upon
stimulation of multiple TLRs to function as a negative
MicroRNAs in atherosclerosis 637regulator of TLR-associated signaling events in macrophages
[98]. The TLR pathways and miRNAs regulation may consti-
tute novel therapeutic targets for atherosclerosis.
MicroRNA in proatherosclerotic mice
Highconcentrations ofdietary cholesterol andcholic acidare
required to develop atherosclerotic plaques in rats [99].
However, mice respond poorly to cholesterol-rich diets and
only develop small fatty streaks in the aortic root [100]. By
using the gene knockout techniques, apolipoprotein E (ApoE)
knockout and LDL receptor (LDLR) knockout mice have been
developed as a mouse model to study atherosclerosis
[101,102]. The high-fat diet is used to induce atherosclerosis
in ApoE knockout mice due to the absence of the ApoE ligand
on chylomicron remnants and very low-density lipoproteins.
In the absence of hepatic LDL receptors, LDLR knockoutmice
become hypercholesterolemic after being fed a potent
cholesterol-rich diet. It is useful to identify the functions of
the gene using these animal models.
Several studies have also used these knockout animal
models to further explore the roles of miRNAs in atheroscle-
rosis.The levels ofmiR-143andmiR-145markedlydecreased in
theaortaofApoEknockoutmicewhen theywere put onahigh-
fat diet [103]. BecausemiR-143 andmiR-145originate fromthe
same transcriptional unit, the miR-143/145 knockout mice
demonstrated that this unit plays a critical role in the reversion
of the VSMC differentiation phenotype [103]. Other miRNAs
that have been tested in animal studies are briefly described
below: levels of miR-125b decreased in the aortas of ApoE
knockoutmice fed a high-fat diet [104]; anti-miR33 showed an
increase in circulating high-density lipoprotein levels and
enhanced reverse cholesterol transport to the plasma, liver,
and feces [105] in LDLR knockout mice; and administration of
miR-126 into mouse models limited atherosclerosis formation
and also stabilized the atherosclerotic plaque [23].
MicroRNA in human atherosclerosis studies
Although several miRNAs have been reported from cellular
and animal studies on atherosclerosis, human data provide
more direct and useful information. Cipollone et al re-
ported that five miRNAsdmiR-100, miR-127, miR-145, miR-
133a, and miR-133bdwere overexpressed in symptomatic
plaques [106]. Among these five miRNAs, miR-145 and miR-
133a were further shown to modulate stroke-related
proteins in vitro.
Li et al demonstrated that the levels of miR-21, miR-
130a, miR-27b, let-7f, and miR-210 increased significantly in
the sclerotic intimal samples compared with normal intimal
samples from the same patients with atherosclerotic oblit-
erans [107], whereas miR-221 and miR-222 decreased
significantly. Furthermore, significant increases in miR-
130a, miR-27b, and miR-210 expression were observed in
the serum. Another study reported that the expressions of
miR-21, miR-34a, miR-146a, miR-146b-5p, and miR-210
were significantly upregulated in human atherosclerotic
arteries versus nonatherosclerotic arteries [46].
Studies have reported that stable miRNAs can be
detected in serum and other body fluids [108]. Thus,
investigating the profiles of circulating miRNAs that arerelated to disease formation may lead to their use as novel
noninvasive biomarkers [109]. Fichtlscherer et al demon-
strated that the circulating levels of miR-126, miR-17, miR-
92a, miR-145, and miR-155 were significantly reduced in
patients with coronary artery disease compared with
healthy controls [110]. In contrast, miR-133a and miR-208a
levels tend to be higher in patients with coronary artery
disease. Yao et al. also reported that the expression of miR-
155 was decreased by approximately 60% in the plasma and
peripheral blood mononuclear cells of patients with acute
coronary syndrome [111]. Conversely, the levels of miR-21
and miR-146a were significantly increased.
Similar to other human association studies, some miRNAs
have been reported in one study but could not be repli-
cated in others. It is clear that more studies are warranted
to clarify the role of these potential miRNAs as either
biomarkers of or functional molecules in human athero-
sclerotic diseases.
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